← 홈

ADC · 림프종

161개 · ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-8 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 161개
ADCBiologicstaleAmerican Society of Clinical On…Phase 2

Vemurafenib and Cobimetinib (Vemurafenib and Cobimetinib)

Lymphoma, Non-Hodgkin; Multiple Myeloma · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+4
효능 ORR 65%임상시험 30상태 RECRUITING
ADCBiologicstaleAscentage Pharma Group Inc.Phase 2

Lisaftoclax (Lisaftoclax)

Diffuse Large B Cell Lymphoma (DLBCL) · Diffuse Large B Cell Lymphoma (DLBCL)

#DiffuseLargeBCellLymphomaDLBCL#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 29상태 RECRUITING
ADCBiologicstaleAmgenPhase 3

calaspargase pegol (calaspargase pegol)

B Acute Lymphoblastic Leukemia; B Lymphoblastic Lymphoma · NK-Cell Lymphoma

#NK-CellLymphoma#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3
임상시험 28상태 RECRUITING
ADCBiologicstaleDaiichi SankyoPhase 2

TDxD (Fam-Trastuzumab Deruxtecan-Nxki, Fam-Trastuzumab Deruxtecan-Nxki (TDxD))

Lymphoma, Non-Hodgkin; Multiple Myeloma · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+4
효능 ORR 71.7%임상시험 27상태 RECRUITING
ADCBiologicstaleSeagenPhase 2

brentuximab vedotin (Adcetris, Consolidation with Brentuximab Vedotin)

Hodgkin Lymphoma, Adult · Hodgkin Lymphoma, Adult

#HodgkinLymphomaAdult#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 25상태 RECRUITING
ADCBiologicstaleNational Cancer Institute (NCI)vedotin, and venetoclax dem…Phase 2

Larotrectinib (Larotrectinib)

Advanced Lymphoma; Advanced Malignant Solid Neoplasm · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+5
효능 ORR 94.4%임상시험 25상태 RECRUITING
ADCBiologicstaleHoffmann-La RochePhase 2

POLA-R-CHP (POLA-R-CHP)

Diffuse Large B Cell Lymphoma (DLBCL) · Diffuse Large B-Cell Lymphoma (DLBCL)

#DiffuseLargeB-CellLymphomaDLBCL#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 95%임상시험 25상태 RECRUITING
ADCBiologicstaleSeagenPhase 2

brentuximab vedotin (Adcetris, Brentuximab Vedotin - induction)

Refractory Peripheral T-Cell Lymphoma; Relapsed Peripheral T-Cell Lymphoma · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 2%임상시험 24상태 ACTIVE
ADCBiologicstaleGlaxoSmithKlinePhase 2

Dabrafenib Mesylate (Dabrafenib Mesylate)

Advanced Lymphoma; Advanced Malignant Solid Neoplasm · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 61%임상시험 24상태 RECRUITING
ADCBiologicstaleTaiho Oncology, Inc.Phase 2

Futibatinib (Futibatinib)

Advanced Solid Tumor · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 47.1%임상시험 23상태 RECRUITING
ADCBiologicstaleMerck Sharp & Dohme LLCPhase 3

Nemtabrutinib (Nemtabrutinib)

Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma; Gastric Mucosa-Associated Lymphoid Tissue Lymphoma · Chronic Lymphocytic Leukemia

#ChronicLymphocyticLeukemia#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 0.0%임상시험 23상태 RECRUITING
ADCBiologicstaleCelgenePhase 2

CC-99282 (CC-99282)

Lymphoma, Non-Hodgkin; Lymphoma, Large B-Cell, Diffuse · Non-Hodgkin Lymphoma

#Non-HodgkinLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 92.9%임상시험 21상태 RECRUITING
ADCBiologicstaleBristol-Myers SquibbPhase 1

Verapamil Hydrochloride (Verapamil Hydrochloride)

Recurrent Hodgkin Lymphoma; Refractory Hodgkin Lymphoma · FRα

#FR#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+3
임상시험 19상태 ACTIVE
ADCBiologicstaleAmgenPhase 3

Haematopoietic growth factor (Haematopoietic growth factor)

Hodgkin Lymphoma · Hodgkin Lymphoma

#HodgkinLymphoma#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+1
임상시험 14상태 RECRUITING
ADCBiologicstaleRochePhase 2

Polatuzumab Vedotin, Rituximab, Lenalidomide (Polatuzumab Vedotin, Rituximab, Lenalidomide)

Diffuse Large B Cell Lymphoma · Diffuse Large B Cell Lymphoma

#DiffuseLargeBCellLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
효능 ORR 100%임상시험 12상태 RECRUITING
ADCBiologicstaleHoffmann-La RochePhase 2

89Zr-Df-IAB22M2C (89Zr-Df-IAB22M2C)

Non-Hodgkins Lymphoma · Non-Hodgkins Lymphoma

#Non-HodgkinsLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 10상태 RECRUITING
ADCBiologicstaleAstraZenecaPhase 3

R-mini-CHOP (R-mini-CHOP)

Large B-cell Lymphoma · DLBCL

#DLBCL#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 94.1%임상시험 10상태 RECRUITING
ADCBiologicstaleGenentech, Inc.Phase 2

Taselisib (Taselisib)

Advanced Lymphoma; Advanced Malignant Solid Neoplasm · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 50%임상시험 10상태 ACTIVE
ADCBiologicstaleMerck Sharp & Dohme LLCPhase 2

Zilovertamab vedotin (Zilovertamab vedotin)

Lymphoma, Large B-Cell, Diffuse · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+4
효능 ORR 1.4%임상시험 10상태 DISCONTINUED
ADCBiologicstaleThe Thai Lymphoma Study GroupPhase 2

B-MAD chemotherapy (B-MAD chemotherapy)

Extranodal NK/T-cell Lymphoma · Extranodal NK/T-cell Lymphoma

#ExtranodalNKT-cellLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 33.3%임상시험 9상태 ACTIVE

4 / 9 페이지

← 이전다음 →